BioNTech (NASDAQ:BNTX) Stock Price Down 3.4%

BioNTech SE (NASDAQ:BNTX)’s share price was down 3.4% on Thursday . The company traded as low as $95.60 and last traded at $95.85. Approximately 236,594 shares were traded during trading, a decline of 67% from the average daily volume of 706,392 shares. The stock had previously closed at $99.27.

Analyst Ratings Changes

BNTX has been the subject of a number of recent research reports. HSBC upgraded BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $94.00 to $91.00 and set an “underweight” rating for the company in a research note on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $113.00 price target on shares of BioNTech in a report on Tuesday, August 27th. TD Cowen reduced their price objective on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $109.09.

BioNTech Stock Performance

The company has a market cap of $24.12 billion, a price-to-earnings ratio of 198.54 and a beta of 0.23. The firm has a 50-day simple moving average of $85.91 and a 200 day simple moving average of $89.37. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company’s quarterly revenue was down 23.3% on a year-over-year basis. During the same period last year, the firm earned ($0.86) EPS. On average, sell-side analysts predict that BioNTech SE will post -2.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Natixis Advisors L.P. purchased a new stake in shares of BioNTech in the fourth quarter valued at approximately $1,663,000. Jump Financial LLC purchased a new stake in shares of BioNTech in the fourth quarter valued at approximately $268,000. QRG Capital Management Inc. boosted its stake in shares of BioNTech by 55.0% in the fourth quarter. QRG Capital Management Inc. now owns 12,587 shares of the company’s stock valued at $1,328,000 after buying an additional 4,466 shares in the last quarter. Quadrant Capital Group LLC purchased a new stake in shares of BioNTech in the fourth quarter valued at approximately $85,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in BioNTech during the fourth quarter worth $5,563,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.